McKesson Corporation Revenue in 2024

McKesson Corporation reported $309.0B in revenue for fiscal year 2024. This represents a decline of 1.2% compared to the 2023 figure of $312.8B.

Revenue grew from $276.4 billion in FY2022 to $312.8 billion in FY2023, then contracted slightly to $308.95 billion in FY2024. The FY2023 peak reflects a combination of pharmaceutical price inflation and volume growth; the FY2024 contraction reflects normalization. On revenues of nearly $309 billion, net income was $3.146 billion — a margin of approximately 1%. That margin is typical for pharmaceutical distribution and reflects the structural reality of operating as an intermediary between powerful manufacturers with pricing leverage and pharmacy chains with their own negotiating scale. Market capitalization of $80 billion on $309 billion in revenue implies a significant premium to the thin-margin distribution business, which is justified by the higher-margin healthcare technology and oncology services segments that have growing revenue contributions. The $6.5 billion in free cash flow generated in FY2024 is the financial metric that explains the market premium: McKesson generates exceptional cash flow relative to its net income because the working capital dynamics of distribution — collecting receivables faster than paying payables — are favorable. The opioid litigation settlement of approximately $8.1 billion, paid over 18 years, is a recurring charge that continues running through the income statement. The Change Healthcare cyberattack in 2024 created operational disruption and financial liability that have not yet been fully quantified in public disclosures. McKesson deployed approximately $1.0 billion in R&D in FY2024, an unusually high figure for a distributor that reflects the technology-intensive nature of its expanded healthcare services operations. The strategic bet — that McKesson can command higher margins by embedding software and analytics into its distribution relationships — depends on continued investment in these capabilities.